You have narrowed it down to two names, and now you are stuck between them. One forum thread champions Mounjaro. The reply underneath swears by Wegovy. A clinic page lists active ingredients you cannot pronounce, another throws around the term GLP-1 without explaining it, and the more you read, the less certain you feel. What you want is not a sales pitch for either, but a plain explanation of how they differ and what really decides which might suit a particular person.
That is what this article sets out to do. It is a comparison written to inform, not to steer you toward either medicine. Both Mounjaro and Wegovy are prescription-only medicines, and neither is presented here as the “best” choice, because there is no single best option that applies to everyone. Whether either is suitable for you is a clinical decision made with a prescriber after an assessment, not something to settle from an article or a comment thread.
What The Two Treatments Have In Common
Before the differences, it helps to see how much these two share, because in many respects they are more alike than different.
Both are prescription-only medicines, so neither can be bought freely and both involve a prescriber from the start. Both are given as a once-weekly injection that begins at a low dose and increases gradually. Both are used as part of a wider weight management programme, alongside changes to diet and activity, rather than on their own. And both depend on a clinical assessment first, followed by ongoing review to monitor how treatment is going and whether it remains appropriate. The framework around them is much the same; the differences sit in the detail.
The Core Difference: One Hormone Pathway Or Two
The central difference is the active ingredient and how it works in the body.
Wegovy contains semaglutide. It acts on a single receptor, GLP-1, so it is described as a GLP-1 receptor agonist. It works through that one appetite-regulation pathway.
Mounjaro contains tirzepatide. It acts on two receptors, GIP and GLP-1, which is why it is described as a dual receptor agonist. In plain terms, it works through two of the body’s appetite-regulation pathways rather than one.
Both pathways are involved in appetite and the feeling of fullness, which is why both medicines are used in weight management. The practical point for a reader is that these are different molecules with different mechanisms, not two brand names for the same thing. Whether that difference matters for any individual is a clinical question, and it is one reason a prescriber assesses each person rather than applying a single rule.
How The Dosing Differs
Both treatments are introduced gradually, but the dose steps differ between them.
Mounjaro follows a stepped pathway through 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. Wegovy follows its own pathway through 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg. The numbers are not comparable across the two, because they are different molecules; a milligram of one is not equivalent to a milligram of the other, and it would be a mistake to read the larger numbers as meaning a stronger medicine.
The shared principle is escalation. Both start low and step up over time, which is intended to help the body adjust and to manage tolerability. The pace, the steps and the dose reached are clinical decisions made for each person, and not everyone moves through every step or reaches the highest dose. This is context only, not dosing advice, and changes to any dose should be made with a prescriber.
What The Clinical Trials Report
Trial data is often where people look for a verdict, so it is worth understanding what the figures are and what they are not.
A head-to-head trial, SURMOUNT-5, compared tirzepatide (Mounjaro) with semaglutide (Wegovy). It reported average weight loss of 20.2% in the tirzepatide group and 13.7% in the semaglutide group over 72 weeks, a relative difference of around 47%. Separately, the SURMOUNT-1 trial of tirzepatide reported an average weight reduction of 20.9% over 72 weeks on the highest dose, with 91% of participants losing at least 5% of their body weight and 57% losing at least 20%.
Those are real, published figures, and they are reported here as fact. But it is important to be clear about what they mean. They are averages from groups of trial participants, measured under trial conditions over many months, not a few weeks. They describe what happened across a population, not what will happen for any one person. They are not individual predictions, and they are not a reason to request a specific medicine.
A higher average in a trial does not mean a given medicine is the right choice for a particular individual. Many factors shape a person’s response, including their health, their history and how they tolerate a treatment. Choosing between treatments is a clinical decision made with a prescriber, based on the whole picture, not a single statistic.
Are The Side Effects Different?
The side-effect profiles of the two treatments are broadly similar, which is unsurprising given they act on shared pathways.
For both, the most commonly reported side effects are digestive: nausea, diarrhoea and constipation. These are often mild to moderate and tend to occur as treatment starts or as the dose increases, easing for many people as the body adjusts. That pattern is not universal, and some people experience side effects differently or for longer. The key point again is individual variation: two people on the same medicine can have different experiences, and the same is true when comparing the two treatments. Side effects, and how well they are tolerated, are part of what a prescriber considers and monitors over time.
Why Suitability Comes Before Comparison
This is the part that the forums and comparison tables tend to miss, and it is the most important point in the article.
There is no universal answer to “which is better”, because suitability is personal. A medicine that is appropriate for one person may not be appropriate for another with a different health profile. Your medical history matters, including conditions and any history that affects which treatments are safe for you. Your current health and the full list of medicines you take matter, because of how treatments can interact. Previous treatment is relevant too; how you have responded to or tolerated something before can shape what comes next. All of this is weighed by a prescriber during an assessment, rather than decided from a leaflet or a thread. The question is not which medicine performs better on average, but which, if either, is appropriate and safe for you as an individual.
Weight Loss Assessments In Surrey
For people considering treatment in Surrey, it helps to understand what an assessment involves.
Easy Clinic is based in Ashford, Surrey, with weight management care led by an Independent Prescriber, supporting patients from Ashford, Chertsey, Walton-on-Thames and the wider Surrey area. The clinic is GPhC registered and has been established since 2008, having cared for over 1,000 patients across a range of services. An assessment looks at your health, your history and your circumstances to consider whether treatment is appropriate and, if so, which option suits you, with monitoring and follow-up as part of the process. This is background rather than a recommendation; whether treatment is right for you is a matter for the assessment itself.
Frequently Asked Questions
Which works better, Mounjaro or Wegovy?
There is no single answer that applies to everyone. A head-to-head trial reported a higher average weight loss with Mounjaro, but trial averages describe groups, not individuals. Which, if either, is appropriate for you depends on your health and history and is decided through clinical assessment.
What is the main difference between them?
Wegovy (semaglutide) acts on one receptor, GLP-1. Mounjaro (tirzepatide) acts on two, GIP and GLP-1. They are different molecules with different mechanisms, both used in weight management. Whether that difference matters for you is a clinical question.
Are the side effects different?
The profiles are broadly similar, with digestive side effects such as nausea, diarrhoea and constipation being the most commonly reported for both. Experiences vary between individuals, and a prescriber will discuss and monitor side effects with you.
Can I choose which one I have?
Treatment is prescribed following a clinical assessment rather than selected from a menu. You can discuss your preferences and questions with the prescriber, but the decision about what is appropriate and safe rests on clinical judgement.
Can I switch from one to the other?
Switching between treatments is sometimes considered, but it is a clinical decision rather than a personal swap. A prescriber would assess whether a change is appropriate for you, taking your history and response into account.
Why are there two options at all?
They are different medicines, with different active ingredients and mechanisms, developed separately. Having more than one option is useful precisely because suitability varies from person to person, which is what an assessment is for.
The Most Important Thing To Remember
Understanding how Mounjaro and Wegovy differ is useful: two prescription-only medicines, different active ingredients, different dosing schedules, broadly similar side-effect profiles, and trial figures that describe groups rather than individuals. What a comparison cannot tell you is which, if either, is right for you. That depends on your health, your history and a clinical assessment, and it is not a decision to make from a forum or an article.
For context, Easy Clinic is a GPhC-registered clinic in Ashford, Surrey, with weight management care led by an Independent Prescriber, established since 2008, supporting patients across the wider Surrey area. If you are weighing up your options, the sensible next step is a conversation with a qualified prescriber who can assess your circumstances and explain what is appropriate for you.
Ready to take the next step?
Book your consultation with Easy Pharmacy in Surrey. Same-day and next-day appointments usually available.
